Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044865 | 0.89 | IKBKB (0.41) | CFTRCHEK1CDK2AP1KMT2AMEN1 | |
| SCHEMBL18044883 | 0.84 | CFTR (0.40) | CFTRCHEK1CDK2AP1 | |
| SCHEMBL18044877 | 0.84 | CFTR (0.38) | CFTRCHEK1 | |
| SCHEMBL18044890 | 0.83 | CFTR (0.40) | CFTRCHEK1 | |
| SCHEMBL18044900 | 0.83 | CFTR (0.40) | CFTRCHEK1 | |
| SCHEMBL18044863 | 0.82 | CFTR (0.36) | CFTRCHEK1CDK2AP1 | |
| SCHEMBL18044866 | 0.82 | CFTR (0.36) | CFTRCHEK1 | |
| SCHEMBL18044885 | 0.81 | CFTR (0.43) | CFTRCHEK1CDK2AP1 | |
| SCHEMBL18044859 | 0.81 | CHEK1 (0.41) | CFTRCHEK1CDK2AP1KMT2AMEN1 | |
| SCHEMBL18044870 | 0.81 | KMT2A (0.51) | CFTRCHEK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867806-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GALAPAGOS NV (BE) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263084-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC3, ABCC5 | CFTR 1/4885CHEK1 3757/4885P2RX7 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.